Focal Segmental Glomerulosclerosis Drugs Market: By Drug Class (Immunosuppressants, Antihypertensive Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

Focal Segmental Glomerulosclerosis Drugs Market size was valued at approximately USD 15,374.2 million and is projected to reach an estimated value of USD 24,207.1 million by 2030. FSGS is a medical condition that describes a pattern of kidney disease defined by sclerosis (scarring) in particular segments (focal) of the kidney's glomeruli, which are its filtering units. Urine is formed by the glomeruli's vital function of filtering waste and extra fluid from the blood. Symptoms of FSGS include Proteinuria (Large amounts of protein “spilling” into the urine), Edema (Swelling in parts of the body, most noticeable around the eyes, hands, feet, and abdomen, which causes sudden weight gain), Low-blood Albumin Levels, High cholesterol in some cases, high blood pressure, increased tendency to form blood clots. The market growth is driven by factors such as the increasing prevalence of FSGS, growing awareness about rare kidney disorders, advancements in drug development targeting specific molecular pathways, and rising healthcare expenditure.

According to the Centres for Disease for Disease Control and Prevention, around 37 million Americans or about 15% of the population are estimated to suffer from chronic kidney disease. The increase in the prevalence of kidney infection is one of the key factors boosting the global focal segmental glomerulosclerosis market size. A person suffering from kidney disease is at higher risk of contracting focal segmental glomerulosclerosis, as both kidney diseases and focal segmental glomerulosclerosis are interrelated. However, the market faces challenges such as the high cost of novel therapies, the limited patient population for clinical trials, and the potential side effects of long-term immunosuppression.

Focal Segmental Glomerulosclerosis Drugs Market Key Developments:

• On February 17, 2023, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
• In 2022, Chinook Therapeutics announced positive Phase 2 results for its drug candidate atrasentan in patients with FSGS.